Stock speculation depends Jin Qilin analyst research report , authoritative, professional, timely and comprehensive, to help you tap potential theme opportunities!
"The King of Price Limits" Dali Pharmaceutical Will be * ST
On the evening of April 25, Dali Pharmaceutical The first quarter report of 2024 was disclosed, and the operating revenue was 15.3203 million yuan, down 58.47% year on year; The net profit loss attributable to the parent company was 5.375 million yuan.
On the same day, Dali Pharmaceutical The announcement of delisting risk warning and suspension of shares was disclosed. The company's shares will be suspended for one day on April 26, and resumed trading and delisting risk warning will be implemented from the opening of the market on April 29. After the delisting risk warning is implemented, the company's shares will be traded on the risk warning board, and the daily rise and fall of the stock price will be limited to 5%.
Since March, the stock price of Dali Pharmaceutical has fluctuated sharply while announcing the risk of being * ST for many times. In March, the stock rose by 123% from the lowest price to the highest price, with 9 consecutive limit ups and 3 limit downs. In April, there were three limits of increase and four limits of decrease again.
Before the annual report, Dali Pharmaceutical has disclosed that the stock may be subject to delisting risk warning for three consecutive times (the abbreviation of the company's stock is preceded by "* ST").
In addition to Dali Pharmaceutical, there are many others who suggest that the stock may be delisted before the annual report. According to the statistics of Databao, up to now, there are still 22 companies that have not disclosed their annual reports and have disclosed that their stocks may be warned of delisting risks this year. The average decline of these stocks this year is 48.37%, of which ST Furun (Rights protection) 、 ST Shentian (Rights protection) The decline exceeded 60%.
On April 24, ST Furun The announcement said that the company had received the Notice of Administrative Punishment in Advance issued by Zhejiang Securities Regulatory Bureau. ST Furun There are false records in 2020 annual report, 2021 annual report and 2022 semi annual report due to fictitious business.
The performance forecast shows that the company expects to achieve an operating income of about 93.5 million yuan in 2023, and the operating income after deducting the business income unrelated to the main business and the income without commercial substance is about 72.9 million yuan; It is estimated that the net profit loss in 2023 will be 400 million yuan to 460 million yuan. The company may be subject to financial forced delisting and be warned of delisting risk due to the fact that the operating income after deduction is less than 100 million yuan and the net profit is negative.
When the stock market recovers, open an account first! Intelligent fixed investment, condition sheet, individual stock radar... for you>>
Massive information, accurate interpretation, all in Sina Finance APP
